By Benjamin Horney (April 5, 2016, 7:25 PM EDT) -- New tax regulations proposed on Monday by the U.S. Treasury Department appeared to take a somewhat direct aim at Pfizer Inc.'s $160 billion agreement to buy Allergan PLC, and it's looking as if the blockbuster inversion deal may very well fall apart, Reuters reported on Tuesday. According to the report, Pfizer is "leaning toward abandoning" the deal, although no official decision has been made as of yet. Under the new tax regulations, benefits that Pfizer had hoped to receive by changing its headquarters to Ireland no longer exist, the report said. Although lawyers for both sides have proposed alternative ways that the inversion could still take place, Pfizer is unwilling to change the deal's terms, the report noted. Other major deals could be affected too, the report added....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
